Ground Swell Capital’s Lipocine LPCN Stock Holding History

Ground Swell Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,185	Closed	-$16K	–	155
2022 Q2	$16K	Buy	+1,185	New	+$18.5K	0.03%	123

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ground Swell Capital's LPCN Position: Q3 2022 in Review

Ground Swell Capital sold out of Lipocine (LPCN) in Q3 2022, closing a stake of 1,185 shares — an estimated $16K sold.

Ground Swell Capital first reported a position in LPCN in Q2 2022 and held it in 1 quarter. The position peaked at $16K in Q2 2022. 46 funds tracked by Wall St. Rank hold LPCN as of Q3 2022.

Ground Swell Capital reported no remaining Lipocine position as of Q3 2022 after selling out during the quarter.
Ground Swell Capital sold 1,185 Lipocine shares in Q3 2022, an estimated $16K.
Ground Swell Capital first reported a position in Lipocine in Q2 2022 and held it in 1 quarter.
Ground Swell Capital's Lipocine position peaked at $16K in Q2 2022.
46 funds tracked by Wall St. Rank held Lipocine as of Q3 2022.

Based on Ground Swell Capital's 13F filing for Q3 2022, filed 14 Nov 2022.